Cargando…

Reduced T-cell Numbers and Elevated Levels of Immunomodulatory Cytokines in Metastatic Prostate Cancer Patients De Novo Resistant to Abiraterone and/or Enzalutamide Therapy

Currently, there are two Food and Drug Administration (FDA)-approved drugs for androgen deprivation therapy (ADT) of metastatic castration-resistant prostate cancer (mCRPC) patients: abiraterone and enzalutamide. However, our understanding of the effect of these therapies on the immune system in mCR...

Descripción completa

Detalles Bibliográficos
Autores principales: Pal, Sumanta K., Moreira, Dayson, Won, Haejung, White, Seok Woon, Duttagupta, Pryanka, Lucia, Marc, Jones, Jeremy, Hsu, JoAnn, Kortylewski, Marcin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6515443/
https://www.ncbi.nlm.nih.gov/pubmed/31013891
http://dx.doi.org/10.3390/ijms20081831
_version_ 1783418093278593024
author Pal, Sumanta K.
Moreira, Dayson
Won, Haejung
White, Seok Woon
Duttagupta, Pryanka
Lucia, Marc
Jones, Jeremy
Hsu, JoAnn
Kortylewski, Marcin
author_facet Pal, Sumanta K.
Moreira, Dayson
Won, Haejung
White, Seok Woon
Duttagupta, Pryanka
Lucia, Marc
Jones, Jeremy
Hsu, JoAnn
Kortylewski, Marcin
author_sort Pal, Sumanta K.
collection PubMed
description Currently, there are two Food and Drug Administration (FDA)-approved drugs for androgen deprivation therapy (ADT) of metastatic castration-resistant prostate cancer (mCRPC) patients: abiraterone and enzalutamide. However, our understanding of the effect of these therapies on the immune system in mCRPC patients remains limited. Here, we examined how abiraterone and enzalutamide treatment affects levels of soluble immune mediators in plasma and in circulating immune cells of 44 mCRPC patients. We found that the baseline levels of cytokines fibroblast growth factor (FGF), granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin 10 (IL-10), and IL-6 were significantly lower in ADT-sensitive compared to de novo resistant patients. In addition, resistant patients showed significantly lower T cell frequencies. When comparing the levels of cytokines over the course of treatment, we observed that the levels of proinflammatory mediators, such as interferon-γ (IFN-γ), IL-5, macrophage inflammatory protein 1 alpha (MIP-1α), and tumor necrosis factor alpha (TNFα), were significantly increased in the ADT-sensitive patients. At the same time, the abiraterone/enzalutamide therapy did not reduce the percentage of tolerogenic myeloid cell populations, such as polymorphonuclear myeloid-derived suppressor cells, which retained unaltered expression of programmed death-ligand 1 (PD-L1) and B7-H3. Overall, our results suggest that certain immune markers, such as IL-6 and the frequency of effector T cells, could be predictive of therapeutic response to ADT therapies in mCRPC patients.
format Online
Article
Text
id pubmed-6515443
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-65154432019-05-30 Reduced T-cell Numbers and Elevated Levels of Immunomodulatory Cytokines in Metastatic Prostate Cancer Patients De Novo Resistant to Abiraterone and/or Enzalutamide Therapy Pal, Sumanta K. Moreira, Dayson Won, Haejung White, Seok Woon Duttagupta, Pryanka Lucia, Marc Jones, Jeremy Hsu, JoAnn Kortylewski, Marcin Int J Mol Sci Article Currently, there are two Food and Drug Administration (FDA)-approved drugs for androgen deprivation therapy (ADT) of metastatic castration-resistant prostate cancer (mCRPC) patients: abiraterone and enzalutamide. However, our understanding of the effect of these therapies on the immune system in mCRPC patients remains limited. Here, we examined how abiraterone and enzalutamide treatment affects levels of soluble immune mediators in plasma and in circulating immune cells of 44 mCRPC patients. We found that the baseline levels of cytokines fibroblast growth factor (FGF), granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin 10 (IL-10), and IL-6 were significantly lower in ADT-sensitive compared to de novo resistant patients. In addition, resistant patients showed significantly lower T cell frequencies. When comparing the levels of cytokines over the course of treatment, we observed that the levels of proinflammatory mediators, such as interferon-γ (IFN-γ), IL-5, macrophage inflammatory protein 1 alpha (MIP-1α), and tumor necrosis factor alpha (TNFα), were significantly increased in the ADT-sensitive patients. At the same time, the abiraterone/enzalutamide therapy did not reduce the percentage of tolerogenic myeloid cell populations, such as polymorphonuclear myeloid-derived suppressor cells, which retained unaltered expression of programmed death-ligand 1 (PD-L1) and B7-H3. Overall, our results suggest that certain immune markers, such as IL-6 and the frequency of effector T cells, could be predictive of therapeutic response to ADT therapies in mCRPC patients. MDPI 2019-04-13 /pmc/articles/PMC6515443/ /pubmed/31013891 http://dx.doi.org/10.3390/ijms20081831 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Pal, Sumanta K.
Moreira, Dayson
Won, Haejung
White, Seok Woon
Duttagupta, Pryanka
Lucia, Marc
Jones, Jeremy
Hsu, JoAnn
Kortylewski, Marcin
Reduced T-cell Numbers and Elevated Levels of Immunomodulatory Cytokines in Metastatic Prostate Cancer Patients De Novo Resistant to Abiraterone and/or Enzalutamide Therapy
title Reduced T-cell Numbers and Elevated Levels of Immunomodulatory Cytokines in Metastatic Prostate Cancer Patients De Novo Resistant to Abiraterone and/or Enzalutamide Therapy
title_full Reduced T-cell Numbers and Elevated Levels of Immunomodulatory Cytokines in Metastatic Prostate Cancer Patients De Novo Resistant to Abiraterone and/or Enzalutamide Therapy
title_fullStr Reduced T-cell Numbers and Elevated Levels of Immunomodulatory Cytokines in Metastatic Prostate Cancer Patients De Novo Resistant to Abiraterone and/or Enzalutamide Therapy
title_full_unstemmed Reduced T-cell Numbers and Elevated Levels of Immunomodulatory Cytokines in Metastatic Prostate Cancer Patients De Novo Resistant to Abiraterone and/or Enzalutamide Therapy
title_short Reduced T-cell Numbers and Elevated Levels of Immunomodulatory Cytokines in Metastatic Prostate Cancer Patients De Novo Resistant to Abiraterone and/or Enzalutamide Therapy
title_sort reduced t-cell numbers and elevated levels of immunomodulatory cytokines in metastatic prostate cancer patients de novo resistant to abiraterone and/or enzalutamide therapy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6515443/
https://www.ncbi.nlm.nih.gov/pubmed/31013891
http://dx.doi.org/10.3390/ijms20081831
work_keys_str_mv AT palsumantak reducedtcellnumbersandelevatedlevelsofimmunomodulatorycytokinesinmetastaticprostatecancerpatientsdenovoresistanttoabirateroneandorenzalutamidetherapy
AT moreiradayson reducedtcellnumbersandelevatedlevelsofimmunomodulatorycytokinesinmetastaticprostatecancerpatientsdenovoresistanttoabirateroneandorenzalutamidetherapy
AT wonhaejung reducedtcellnumbersandelevatedlevelsofimmunomodulatorycytokinesinmetastaticprostatecancerpatientsdenovoresistanttoabirateroneandorenzalutamidetherapy
AT whiteseokwoon reducedtcellnumbersandelevatedlevelsofimmunomodulatorycytokinesinmetastaticprostatecancerpatientsdenovoresistanttoabirateroneandorenzalutamidetherapy
AT duttaguptapryanka reducedtcellnumbersandelevatedlevelsofimmunomodulatorycytokinesinmetastaticprostatecancerpatientsdenovoresistanttoabirateroneandorenzalutamidetherapy
AT luciamarc reducedtcellnumbersandelevatedlevelsofimmunomodulatorycytokinesinmetastaticprostatecancerpatientsdenovoresistanttoabirateroneandorenzalutamidetherapy
AT jonesjeremy reducedtcellnumbersandelevatedlevelsofimmunomodulatorycytokinesinmetastaticprostatecancerpatientsdenovoresistanttoabirateroneandorenzalutamidetherapy
AT hsujoann reducedtcellnumbersandelevatedlevelsofimmunomodulatorycytokinesinmetastaticprostatecancerpatientsdenovoresistanttoabirateroneandorenzalutamidetherapy
AT kortylewskimarcin reducedtcellnumbersandelevatedlevelsofimmunomodulatorycytokinesinmetastaticprostatecancerpatientsdenovoresistanttoabirateroneandorenzalutamidetherapy